Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| CYTOKINETICS INCCYTK · Entity 3528 | Director | May 27, 2026 | May 27, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,808 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 163,808 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
CYTOKINETICS INC
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,361 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,851 · Balance 26,361 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.15 · Expires 2036-05-26 | Direct | 4,301 |
Reported balance
After 2026-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-27 · Grant · Acquired 4,301 · Balance 4,301 |
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,403 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 36,403 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
VERACYTE, INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,718 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 1,864 · Balance 42,718 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,864 | $42.97 | $80,096.08 |
DisclosureSEC source: 0001846905-26-000006 · wk-form4_1788468511.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,718 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 2, 2026. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 39,715 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001846905-26-000004 · wk-form4_1781813041.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,715 Underlying: Common Stock · 39,715 shares Expires 2036-06-16 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 26,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001846905-26-000004 · wk-form4_1781813041.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,808 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 5,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001846905-26-000002 · wk-form4_1781556942.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,582 F1 · kind: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 22:57 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 13,300 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001193125-26-266230 · ownership.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2036-06-08 F2 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 22:57 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-266230 · ownership.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,403 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 4,301 | $0.00 Strike: $77.15 | $0.00 |
DisclosureSEC source: 0001061983-26-000062 · form4.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,301 Underlying: Common Stock · 4,301 shares Expires 2036-05-26 Read SEC document |
| May 27, 2026 Filed May 27, 2026 23:16 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000062 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,361 Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:39 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 54,059 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001628280-25-032725 · wk-form4_1750725535.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,059 Underlying: Common Stock · 54,059 shares Expires 2035-06-18 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 18, 2025 Filed Jun 24, 2025 00:39 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 41,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032725 · wk-form4_1750725535.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,353 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000094 · wk-form4_1750709375.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,310 F1 · kind: Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,589 | $26.67 | $122,366.60 |
DisclosureSEC source: 0001384101-25-000079 · wk-form4_1750191655.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,989 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 11, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $26.39 to $26.92. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:27 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,450 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0000950170-25-086243 · ownership.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,450 Underlying: Common Stock · 11,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:27 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086243 · ownership.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,203 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 15, 2025 Filed May 15, 2025 22:51 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,454 | $29.73 | $43,227.42 |
DisclosureSEC source: 0001127602-25-014556 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,510 Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,880 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014365 · form4.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2035-05-13 F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. Read SEC document |
| May 14, 2025 Filed May 14, 2025 23:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 7,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014365 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,964 F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:24 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 265 | $8.50 | $2,252.50 |
DisclosureSEC source: 0000950170-25-061881 · ownership.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,203 F1 · kind: The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 27, 2024. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:17 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 265 | $9.97 | $2,642.05 |
DisclosureSEC source: 0000950170-25-011757 · ownership.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,468 F1 · kind: The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 27, 2024. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 22:53 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 40,243 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001628280-24-028602 · wk-form4_1718664795.xml · derivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,243 Underlying: Common Stock · 40,243 shares Expires 2034-06-14 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:48 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 11,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000102 · wk-form4_1718657310.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,578 F1 · kind: Restricted stock units awarded on June 13, 2024 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:18 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,515 | $0.00 Strike: $25.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073685 · ownership.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 11,515 shares Expires 2034-06-11 F2 · derivative.exercise_date: This option was granted on June 12, 2024 with respect to 11,515 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:18 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073685 · ownership.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,733 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 20:15 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $52.07 | $104,140.00 |
DisclosureSEC source: 0001127602-24-018246 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,631 Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,870 | $20.32 | $78,633.76 |
DisclosureSEC source: 0001384101-24-000086 · wk-form4_1718137320.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,105 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 27, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $19.97 to $20.88. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:41 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,539 | $21.00 | $32,319.00 |
DisclosureSEC source: 0001384101-24-000069 · wk-form4_1717101697.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,975 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 27, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 22:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 3,636 | $0.00 Strike: $60.50 | $0.00 |
DisclosureSEC source: 0001127602-24-015725 · form4.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,636 Underlying: Common Stock · 3,636 shares Expires 2034-05-15 Read SEC document |
| May 15, 2024 Filed May 16, 2024 22:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015725 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,631 Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:42 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 265 | $23.90 | $6,333.50 |
DisclosureSEC source: 0001209191-23-054163 · doc4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,996 F1 · kind: The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 265 | $42.33 | $11,217.45 |
DisclosureSEC source: 0001209191-23-044257 · doc4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,261 F1 · kind: The reported sale of 265 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023. Read SEC document |
| July 07, 2023 Filed Jul 7, 2023 20:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $34.12 | $68,234.60 |
DisclosureSEC source: 0001127602-23-020455 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,031 Read SEC document |
| July 06, 2023 Filed Jul 10, 2023 21:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,867 | $39.30 | $73,373.10 |
DisclosureSEC source: 0001209191-23-041951 · doc4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,526 F1 · kind: The reported sale of 1,867 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 8, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.74, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 6, 2023 at each separate price. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 100 | $27.09 | $2,709.00 |
DisclosureSEC source: 0001384101-23-000128 · wk-form4_1687380927.xml · nonDerivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,514 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 27, 2023. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,793 | $26.42 | $153,076.55 |
DisclosureSEC source: 0001384101-23-000128 · wk-form4_1687380927.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,614 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 27, 2023. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $26.08 to $27.07. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 22:32 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 49,237 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001628280-23-022558 · wk-form4_1686954708.xml · derivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,237 Underlying: Common Stock · 49,237 shares Expires 2033-06-15 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:24 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 6,473 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037860 · doc4.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473 Underlying: Common Stock · 6,473 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:24 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 4,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037860 · doc4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,393 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:21 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-23-000122 · wf-form4_168669126274077.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,407 F1 · kind: Restricted stock units awarded on June 9, 2023 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:06 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,539 | $25.91 | $39,875.49 |
DisclosureSEC source: 0001384101-23-000072 · wf-form4_168565356637516.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,733 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 27, 2023. Read SEC document |
| May 10, 2023 Filed May 18, 2023 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001127602-23-016157 · form4.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-10 F2 · kind: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024. Read SEC document |
| May 10, 2023 Filed May 18, 2023 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016157 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,031 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 220 | $51.11 | $11,244.20 |
DisclosureSEC source: 0001127602-22-023697 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,031 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of the Issuer's common stock on October 3, 2022. Read SEC document |
| July 01, 2022 Filed Jul 12, 2022 20:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 274 | $41.00 | $11,234.00 |
DisclosureSEC source: 0001127602-22-019228 · form4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,811 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $41.00, representing the closing stock price of the Issuer's common stock on July 1, 2022. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 00:12 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 14,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000096 · wf-form4_165542471995449.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,272 F1 · kind: Restricted stock units awarded on June 16, 2022 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:21 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001567619-22-013084 · doc1.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-15 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:21 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 95,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013084 · doc1.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,802 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 2,980 | $0.00 Strike: $38.49 | $0.00 |
DisclosureSEC source: 0001209191-22-037588 · doc4.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,980 Underlying: Common Stock · 2,980 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 2,980 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:19 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 2,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037588 · doc4.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,968 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001061983-22-000115 · edgardoc.xml · derivative · entry 2 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-10 F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2022 and the last such installment vesting on 05/10/2023. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000115 · edgardoc.xml · nonDerivative · entry 1 Bhanji Muna · CIK 0001846905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,537 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.